BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 34751517)

  • 1. Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer.
    Zhang Z; Zhang H; Li C; Xiang Q; Xu L; Liu Q; Pang X; Zhang W; Zhang H; Zhang S; Duan X; Liu Y; Cui Y
    Thorac Cancer; 2021 Dec; 12(24):3396-3406. PubMed ID: 34751517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer.
    Zhu W; Liu M; Fan Y; Ma F; Xu N; Xu B
    Cancer Med; 2018 Sep; 7(9):4420-4433. PubMed ID: 30099860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients.
    Kassem NM; Makar WS; Kassem HA; Talima S; Tarek M; Hesham H; El-Desouky MA
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2749-2755. PubMed ID: 31554373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the Role of Circulating MicroRNAs to Aid Therapeutic Decision Making for Neoadjuvant Chemotherapy in Breast Cancer: A Prospective, Multicenter Clinical Trial.
    Davey MG; Casey MC; McGuire A; Waldron RM; Paganga M; Holian E; Newell J; Heneghan HM; McDermott AM; Keane MM; Lowery AJ; Miller N; Kerin MJ
    Ann Surg; 2022 Nov; 276(5):905-912. PubMed ID: 35876391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer.
    Liu B; Su F; Chen M; Li Y; Qi X; Xiao J; Li X; Liu X; Liang W; Zhang Y; Zhang J
    Hum Pathol; 2017 Jun; 64():44-52. PubMed ID: 28412211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of circulating miR-21, -205, and -182 with response of luminal breast cancers to neoadjuvant FAC and AC treatment.
    Chekhun VF; Borikun TV; Bazas VМ; Andriiv AV; Klyusov OМ; Yalovenko TМ; Lukianova NY
    Exp Oncol; 2020 Sep; 42(3):162-166. PubMed ID: 32996748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.
    Raychaudhuri M; Bronger H; Buchner T; Kiechle M; Weichert W; Avril S
    Breast Cancer Res Treat; 2017 Apr; 162(3):511-521. PubMed ID: 28181130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    Resende U; Cabello C; Ramalho SOB; Zeferino LC
    BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
    Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
    Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR-34a and miR-122 Expression.
    Frères P; Josse C; Bovy N; Boukerroucha M; Struman I; Bours V; Jerusalem G
    J Cell Physiol; 2015 Feb; 230(2):473-81. PubMed ID: 25078559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer.
    Liu Z; Yu B; Su M; Yuan C; Liu C; Wang X; Song X; Li C; Wang F; Ma J; Wu M; Chen D; Yu J; Yu Z
    BMC Med; 2023 Dec; 21(1):493. PubMed ID: 38087296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).
    Robelin P; Tod M; Colomban O; Lachuer J; Ray-Coquard I; Rauglaudre G; Joly F; Chevalier-Place A; Combe P; Lortholary A; Hamizi S; Raban N; Ferron G; Meunier J; Berton-Rigaud D; Alexandre J; Kaminsky MC; Dubot C; Leary A; Malaurie E; You B
    Gynecol Oncol; 2020 Oct; 159(1):256-263. PubMed ID: 32712155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Neutrophil to Lymphocyte Ratio Predicts the Response to Neoadjuvant Chemotherapy in Luminal B Breast Cancer.
    Rivas M; Acevedo F; Dominguez F; Galindo H; Camus M; Oddo D; Villarroel A; Razmilic D; Peña J; Munoz Medel M; Navarro ME; Perez-Sepulveda A; Medina L; Merino T; Briones J; Kalergis A; Sanchez C
    Asian Pac J Cancer Prev; 2019 Jul; 20(7):2209-2212. PubMed ID: 31350986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment.
    Al-Khanbashi M; Caramuta S; Alajmi AM; Al-Haddabi I; Al-Riyami M; Lui WO; Al-Moundhri MS
    PLoS One; 2016; 11(4):e0152032. PubMed ID: 27064979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
    Yang X; Rao J; Yang W; Shui R
    Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy.
    Cabrera-Galeana P; Muñoz-Montaño W; Lara-Medina F; Alvarado-Miranda A; Pérez-Sánchez V; Villarreal-Garza C; Quintero RM; Porras-Reyes F; Bargallo-Rocha E; Del Carmen I; Mohar A; Arrieta O
    Oncologist; 2018 Jun; 23(6):670-678. PubMed ID: 29490940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miRNAs as therapeutic predictors and prognostic biomarkers of neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.
    Zhang Z; Zhang H; Yu J; Xu L; Pang X; Xiang Q; Liu Q; Cui Y
    Breast Cancer Res Treat; 2022 Aug; 194(3):483-505. PubMed ID: 35727379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graphene Oxide-Based Highly Sensitive Assay of Circulating MicroRNAs for Early Prediction of the Response to Neoadjuvant Chemotherapy in Breast Cancer.
    Li Z; Xiao H; Li J; Yang Z; Jiang J; Ji J; Peng C; He Y
    Anal Chem; 2022 Nov; 94(46):16254-16264. PubMed ID: 36342865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.